(vianews) - merck and co inc (mrk.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| merck and co inc (mrk.pa) | €101.60 | 2.61% | 29.69% |
| iba (ibab.br) | €15.12 | 1.24% | 5.01% |
| tubize-fin (tub.br) | €71.00 | 1.18% | 4.93% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. merck and co inc (mrk.pa)
2.61% forward dividend yield and 29.69% return on equity
merck & co., inc. operates as a healthcare company worldwide. it operates through two segments, pharmaceutical and animal health. the pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. the animal health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. the company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. it has collaborations with astrazeneca plc; bayer ag; eisai co., ltd.; ridgeback biotherapeutics lp; and gilead sciences, inc. to jointly develop and commercialize long-acting treatments in hiv. merck & co., inc. was founded in 1891 and is headquartered in rahway, new jersey.
earnings per share
as for profitability, merck and co inc has a trailing twelve months eps of €4.78.
pe ratio
merck and co inc has a trailing twelve months price to earnings ratio of 21.26. meaning, the purchaser of the share is investing €21.26 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 29.69%.more news about merck and co inc.
2. iba (ibab.br)
1.24% forward dividend yield and 5.01% return on equity
ion beam applications sa develops, manufactures, and supports medical devices and software solutions for cancer treatments in belgium, the united states, and internationally. the company operates through proton therapy and other accelerators, and dosimetry segments. the proton therapy and other accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. this segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or spect radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. the dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. the company has strategic research and development partnership with sck cen (belgian nuclear research center) to enable the production of actinimum-225 (225ac), a novel radioisotope for the treatment of cancer; and an agreement with university of pennsylvania for research in conformalflash. ion beam applications sa was incorporated in 1986 and is headquartered in louvain-la-neuve, belgium.
earnings per share
as for profitability, iba has a trailing twelve months eps of €0.2.
pe ratio
iba has a trailing twelve months price to earnings ratio of 75.6. meaning, the purchaser of the share is investing €75.6 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.01%.dividend yield
as maintained by morningstar, inc., the next dividend payment is on jun 29, 2022, the estimated forward annual dividend rate is 0.19 and the estimated forward annual dividend yield is 1.24%.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, iba's stock is considered to be overbought (>=80).
revenue growth
year-on-year quarterly revenue growth grew by 14.5%, now sitting on 361.27m for the twelve trailing months.
more news about iba.
3. tubize-fin (tub.br)
1.18% forward dividend yield and 4.93% return on equity
financière de tubize sa, through its interest in ucb, operates as a biopharmaceutical company worldwide. it discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. the company's products include cimzia for treating ankylosing spondylitis, axial spondyloarthritis, crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; briviact, vimpat, and keppra for the treatment of epilepsy partial-onset seizures; nayzilam, a nasal spray; and neupro for treating parkinson's disease and restless legs syndrome. it also offers evenity, an injection for osteoporosis; and bimzelx to treat moderate to severe plaque psoriasis. the company's products in pipeline include staccato to treat stereotypical prolonged seizures; bepranemab for the treatment of alzheimer's disease; ucb0599 for parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. financière de tubize sa is based in brussels, belgium.
earnings per share
as for profitability, tubize-fin has a trailing twelve months eps of €1.91.
pe ratio
tubize-fin has a trailing twelve months price to earnings ratio of 37.17. meaning, the purchaser of the share is investing €37.17 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.93%.more news about tubize-fin.